---
layout: post
title: 报道：英国正在调查诺和诺德糖尿病、减肥药物的副作用
date: 2023-07-27 08:33:04.000000000 +08:00
link: https://cn.wsj.com/amp/articles/%E6%8A%A5%E9%81%93-%E8%8B%B1%E5%9B%BD%E6%AD%A3%E5%9C%A8%E8%B0%83%E6%9F%A5%E8%AF%BA%E5%92%8C%E8%AF%BA%E5%BE%B7%E7%B3%96%E5%B0%BF%E7%97%85-%E5%87%8F%E8%82%A5%E8%8D%AF%E7%89%A9%E7%9A%84%E5%89%AF%E4%BD%9C%E7%94%A8-6daccd25
categories: wsj
---

<main id="main" role="main">
<div>


</div>
<div itemprop="articleLead" data-sbId="CN-BIZ-20230727074748">
    <div>
      <div class="media-object scope-
          header
">
          <figure>
      <div>
        <img
          srcset="https://images.wsj.net/im-814195?width=540&amp;size=1.5005861664712778 540w, https://images.wsj.net/im-814195?width=620&amp;size=1.5005861664712778 620w, https://images.wsj.net/im-814195?width=639&amp;size=1.5005861664712778 639w, https://images.wsj.net/im-814195?width=860&amp;size=1.5005861664712778 860w, https://images.wsj.net/im-814195?width=860&amp;size=1.5005861664712778&amp;pixel_ratio=1.5 1290w, https://images.wsj.net/im-814195?width=860&amp;size=1.5005861664712778&amp;pixel_ratio=2 1720w, https://images.wsj.net/im-814195?width=860&amp;size=1.5005861664712778&amp;pixel_ratio=3 2580w"
          src="https://images.wsj.net/im-814195?width=860&amp;height=573"
          layout="responsive"
          placeholder
          alt="">
        </img>
      </div>
      <figcaption>
        <p>一支总部位于丹麦的诺和诺德生产的诺和泰。</p>
    <p> 图片来源：F. Martin Ramin/The Wall Street Journal</p>
  </figcaption>
</figure>

      </div>
    </div>
</div>
<div data-sbId="CN-BIZ-20230727074748">

<div>

  <div>
      <p> </p>
              <p><span itemprop="name">
                <a href="https://www.wsj.com/news/author/dominic-chopping" itemprop="url" rel="author">Dominic Chopping</a>
              </span></p>

  </div>
    <time>
      2023年7月27日08:00 CST 更新
    </time>
</div>

<div subscriptions-actions subscriptions-display="NOT data.noSharing">
  <div>
    <social-share type="system" width="72" height="24"
      data-param-url="https://cn.wsj.com/articles/报道-英国正在调查诺和诺德糖尿病-减肥药物的副作用-6daccd25">
    </social-share>
  </div>
</div>


<div subscriptions-section="content">
</div>
<div subscriptions-section="content-not-granted">
</div>



<section subscriptions-section="content">
      <p>据路透(Reuters)<a href="https://tinyurl.com/27xzxvud" target="_blank" >报道</a>，在一些患者报告有自杀或自残念头后，英国医疗监管机构正在审查诺和诺德(Novo Nordisk, NVO)销售的一类用于治疗糖尿病和减肥的药物。</p>
      <p>据路透报道，英国药物及保健产品规管局(MHPRA)告诉路透，该机构正在审查一类被称为GLP-1受体激动剂的药物的安全数据，其中包括诺和诺德的Ozempic 2型糖尿病治疗药物和减肥治疗药物Saxenda。</p>
      <p><em>（本文来自道琼斯通讯社）</em></p>
      <p><strong>相关阅读：</strong></p>
      <div> <p><a href="https://cn.wsj.com/articles/CN-BIZ-20230711074016" target="_blank" >欧盟调查减肥药诺和泰是否会增加自杀倾向</a></p>
      <p><a href="https://cn.wsj.com/articles/CN-BIZ-20230414083047" target="_blank" >“金刚级”减肥药将至</a></p>
      </div>
</section>

</div>
      </main>
